期刊文献+

血液透析联合血液灌流对维持性血液透析患者甲状旁腺激素清除的应用研究 被引量:11

Application Study of Hemodialysis Combined With Hemoperfusion on Parathyroid Hormone Clearance in Maintenance Hemodialysis Patients
下载PDF
导出
摘要 目的观察血液透析联合血液灌流治疗对维持性血液透析患者甲状旁腺激素清除的疗效研究。方法选取本院2019年1月—2020年6月行维持性血液透析且合并有甲状旁腺激素异常升高的28例患者,随机分为两组,对照组采用单纯血液透析治疗模式,观察组采用血液透析联合血液灌流治疗模式,观察治疗前后甲状旁腺激素水平下降情况。结果观察组经3个月治疗后甲状旁腺激素下降明显,差异具有统计学意义,而对照组则下降不明显,差异无统计学意义。结论血液透析联合血液灌流更能有效地清除维持性血液透析患者异常升高的甲状旁腺激素水平,减轻相关临床症状。 Objective To observe the effect of hemodialysis combined with hemoperfusion on parathyroid hormone clearance in maintenance hemodialysis patients.Methods From January 2019 to June 2020,28 patients with abnormal parathyroid hormone were randomly divided into two groups.The control group was treated with simple hemodialysis,the observation group was treated with hemodialysis and hemoperfusion,and the decrease of parathyroid hormone level before and after treatment was observed.Results After 3 months of treatment,parathyroid hormone in the observation group decreased significantly,the difference was statistically significant,while that in the control group was not significant,the difference was not statistically significant.Conclusion Hemodialysis combined with hemoperfusion can effectively remove the abnormally high level of parathyroid hormone in maintenance hemodialysis patients,and reduce the related clinical symptoms.
作者 林金平 黄泽燕 林国贤 林彩霞 刘晶晶 LIN Jinping;HUANG Zeyan;LIN Guoxian;LIN Caixia;LIU Jingjing(Hemodialysis Center,Quangang District Hospital,Quanzhou Fujian 362800,China)
出处 《中国卫生标准管理》 2021年第2期65-67,共3页 China Health Standard Management
基金 福建省泉州市泉港区科技计划项目(2019S04)。
关键词 维持性血液透析 血液灌流 甲状旁腺激素 清除 高血压肾病 临床症状 maintenance hemodialysis hemoperfusion parathyroid hormone clearance hypertensive nephropathy clinical symptoms
  • 相关文献

参考文献10

二级参考文献62

  • 1孙桂云.血液透析中透析器凝血的原因及处理[J].青海医药杂志,2012,42(5):38-39. 被引量:4
  • 2汤兵,宋宗纬,侯大卫,赵庆洪,曹红娣,张桦,闻萍,方丽,熊明霞,叶红,许小飞,张平,王蔚蔚,杨俊伟.62例次继发性甲状旁腺功能亢进症行甲状旁腺切除术的临床分析[J].中国血液净化,2012,11(7):374-378. 被引量:38
  • 3陈香美,初启江.不同血液净化方式对蛋白结合类毒素的清除作用[J].中国血液净化,2005,4(11):581-584. 被引量:50
  • 4D’Amour P. Circulating PTH molecular forms: what weknow and what we don’t[J]. Kidney Int, 2006, ?102):S29~33.
  • 5Juppner H, Potts JT Jr. Immunoassays for the detectionof parathyroid hormone[J]. J Bone Miner Res, 2002, 17(Suppl 2):N81-86.
  • 6Berson SA, Yalow RS, Aurbach GD, et al. Immunoassay ofbovine and human parathyroid hormone[J]. Proc NatlAcad Sci USA, 1963,49(5):613-617.
  • 7Nussbaum SR, Zahradnik RJ, Lavigne JR, et al. Highlysensitive two-site immunoradiometric assay of parathy-rin, and its clinical utility in evaluating patientswith hypercalcemia[J]. Clin Chem,1987,33(8):1364 - 1367.
  • 8Lepage R, Roy L, Brossard JH, et al. A non- (1-84) cir-culating parathyroid hormone (PTH) fragment interferessignificantly with intact PTH commercial assay measure-ments in uremic samples[J]. Clin Chem, 1998,44(4):805-809.
  • 9Nguyen-Yamamoto L, Rousseau L, Brossard JH, et al. Syn-thetic carboxyl-terminal fragments of parathyroid hor-mone (PTH) decrease ionized calcium concentration inrats by acting on a receptor different from the PTH/PTH-related peptide receptor[J]. Endocrinology, 2001,142 (4) :1386-1392.
  • 10Langub MC, Monier-Faugere MC, Wang G, et al. Adminis-tration of PTH- (7-84) antagonizes the effects of PTH-(1-84) on bone in rats with moderate renal failure[J],Endocrinology, 2003, 144(4):1135-1138.

共引文献97

同被引文献108

引证文献11

二级引证文献57

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部